Last reviewed · How we verify
Doxycycline Tablets
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation and bacterial growth.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation and bacterial growth. Used for Bacterial infections including respiratory tract infections, urinary tract infections, and skin infections, Malaria prophylaxis and treatment, Acne vulgaris.
At a glance
| Generic name | Doxycycline Tablets |
|---|---|
| Also known as | Doxycycline, Erythrocyte sedimentation rate (ESR), Complete blood count (CBC)., Lipid profile, Renal and liver function tests |
| Sponsor | Yaounde Central Hospital |
| Drug class | Tetracycline antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Doxycycline is a tetracycline antibiotic that binds reversibly to the bacterial 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex. This inhibits protein synthesis and is bacteriostatic, stopping bacterial growth and allowing the immune system to clear the infection. It is effective against a broad spectrum of gram-positive and gram-negative bacteria, as well as some atypical organisms.
Approved indications
- Bacterial infections including respiratory tract infections, urinary tract infections, and skin infections
- Malaria prophylaxis and treatment
- Acne vulgaris
- Lyme disease
- Chlamydial infections
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Photosensitivity
- Esophageal irritation
- Vaginal candidiasis
- Headache
Key clinical trials
- FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Ocular Rosacea Biome Study (PHASE4)
- Efficacy of Oral Metformin vs Oral Doxycycline in Treating Acne Vulgaris (PHASE4)
- Doxycycline for Elbow Tendinopathy (PHASE1)
- Got Doxy- 'Flipping the Script' on STI PEP (PHASE4)
- Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Doxycycline Tablets CI brief — competitive landscape report
- Doxycycline Tablets updates RSS · CI watch RSS
- Yaounde Central Hospital portfolio CI